Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
Cosmos Health CEO Greg Siokas issued a shareholder letter reporting preliminary nine-month 2026 revenue of approximately $54.3 million, up 19% year over year, and reaffirmed guidance that full-year 2026 revenue will surpass $90 million. The letter highlights a fast-scaling U.S. direct-to-consumer subscription business — 8,940 active subscriptions as of October 19, ~$1.3M in monthly subscription value, and an expected ~$15M of Q4 revenue at ~70% gross margin — plus a sixfold expansion of the Cana Laboratories CMO pipeline to 32.7 million units.
Key figures
- Revenue
- $54.3 million
- Guidance
- FY2026 revenue to surpass $90 million (reaffirmed); FY2029 revenue target $200.6M, gross margin ~35.5%, adjusted EBITDA $44.2M
- Revenue Yoy
- 19%
- Fy2025 revenue
- $65.3 million
- Q3 2026 revenue
- $17.4 million
- Cmo pipeline units
- 32.7 million units (up sixfold since mid-2024)
- Implied q4 revenue
- $35.7 million
- Shares repurchased
- 5.1 million shares for ~$1.1 million under $5.0M program
- Fy2025 gross margin
- 12.1%
- Us active subscriptions
- 8940
- Total liabilities change
- -13.3% (Dec 31, 2025 to Jun 30, 2026)
- Us q4 revenue expectation
- $15 million
- Monthly subscription value
- $1,325,338
- Us gross margin expectation
- ~70%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.